
Lowering PSA cutoffs to enhance detection of curable prostate cancer
2000; Elsevier BV; Volume: 55; Issue: 6 Linguagem: Inglês
10.1016/s0090-4295(99)00602-0
ISSN1527-9995
AutoresWilliam J. Catàlona, Christian G. Ramos, Gustavo Franco Carvalhal, Ying Yan,
Tópico(s)Bladder and Urothelial Cancer Treatments
ResumoThe widespread use of serum prostate-specific antigen (PSA) testing for early prostate cancer detection has increased the proportion of early-stage cancers detected and is at least partially responsible for the recent decrease in prostate cancer mortality rates in the United States.1
Referência(s)